BioCentury | Jun 13, 2019
Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

...in a Phase IIa trial to treat major depressive disorder. BRTX246040 was an antagonist of OPRL1...
...Polaris’ Brian Chee joined BlackThorn’s board. Targets: KOR - Kappa opioid receptor; OPRL1 (NOPR) - opioid related nociceptin receptor 1...
BioCentury | Jun 3, 2019
Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

...treat OUD in 2002 Partial MOR agonist, κ opioid receptor (KOR; OPRK1) antagonist, opioid related nociceptin receptor 1 (OPRL1; NOPR...
BioCentury | Jan 11, 2019
Clinical News

BlackThorn deprioritizing MDD compound after Phase IIa miss

...Anhedonia Rating Scale (DARS) and Snaith-Hamilton Pleasure Scale (SHAPS) scores. BlackThorn has rights to the OPRL1...
...NYSE:LLY), Indianapolis, Ind. Product: BTRX-246040 (formerly LY-2940094) Business: Neurology Molecular target: Opioid related nociceptin receptor 1 (OPRL1; NOPR) Description: OPRL1...
...DARS) and Snaith-Hamilton Pleasure Scale (SHAPS) Status: Phase IIa data Milestone: NA Brian Moy BTRX-246040, ly-2940094 BlackThorn Therapeutics Inc. Opioid related nociceptin receptor 1 (OPRL1) (NOPR) Depression...
BioCentury | Sep 7, 2018
Clinical News

Bifunctional agonist could treat pain, opioid dependency

...but can lead to misuse, addiction and overdose. Agonists targeting another opioid receptor, opioid related nociceptin receptor 1 (OPRL1; NOPR...
...the researchers used structure-based chemical synthesis to develop a bifunctional partial agonist targeting MOR and OPRL1...
...Treat pain and opioid dependency Chris Lieu Astraea Therapeutics LLC Wake Forest Baptist Medical Center Mu opioid receptor (MOR) (OPRM1) Opioid related nociceptin receptor 1 (OPRL1) (NOPR)...
BioCentury | Aug 29, 2018
Preclinical News

Bifunctional agonist could treat pain, opioid dependency

...but can lead to misuse, addiction and overdose. Agonists targeting another opioid receptor, opioid related nociceptin receptor 1 (OPRL1; NOPR...
...the researchers used structure-based chemical synthesis to develop a bifunctional partial agonist targeting MOR and OPRL1...
...preparation for filing an IND. Chris Lieu Astraea Therapeutics LLC Wake Forest Baptist Medical Center Mu opioid receptor (MOR) (OPRM1) Opioid related nociceptin receptor 1 (OPRL1) (NOPR)...
BioCentury | Aug 10, 2018
Company News

BlackThorn licenses Yale's neuroimaging tech

...against those targets. The company has two compounds in the clinic: BTRX-246040, an opioid related nociceptin receptor 1 (OPRL1; NOPR...
BioCentury | Aug 6, 2018
Company News

BlackThorn licenses Yale's neuroimaging drug discovery tech

...against those targets. The company has two compounds in the clinic: BTRX-246040, an opioid related nociceptin receptor 1 (OPRL1; NOPR...
BioCentury | Jun 8, 2018
Clinical News

BlackThorn brings KOR antagonist into clinic

...BlackThorn's second compound to enter the clinic. Its lead program, BTRX-246040, is an opioid related nociceptin receptor 1 (OPRL1; NOPR...
BioCentury | May 15, 2018
Distillery Therapeutics

Neurology

...INDICATION: Spinal cord injury (SCI) Cell culture and mouse studies suggest antagonizing OPRL1 alone or in...
...help treat SCI. In primary mouse cortical neurons subjected to scrape injury, an shRNA targeting OPRL1...
...OPRL1 antagonist, in Phase II testing to treat depression and neurobehavioral disorders. TARGET/MARKER/PATHWAY: Opioid related nociceptin receptor 1 (OPRL1; NOPR...
BioCentury | Jul 28, 2017
Product Development

Circuit logic

...Phase IIa study of lead program BTRX-246040 , an antagonist of opioid related nociceptin receptor 1 ( OPRL1 ; NOPR...
...that appeared to be driven by subpopulations of responders. BlackThorn said INFORM has shown that OPRL1...
...behavioral tasks or neuroimaging patterns. First test Martin said BlackThorn had a general interest in OPRL1...
Items per page:
1 - 10 of 17